Arovella Therapeutics (FRA:E4NA) 3-Year EBITDA Growth Rate : 39.90% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Arovella Therapeutics 3-Year EBITDA Growth Rate?

Arovella Therapeutics's EBITDA per Share for the six months ended in Dec. 2023 was €-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 39.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 37.40% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 12.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Arovella Therapeutics was 48.80% per year. The lowest was -75.00% per year. And the median was 10.50% per year.

Competitive Comparison of Arovella Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Arovella Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's 3-Year EBITDA Growth Rate falls into.

Arovella Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Arovella Therapeutics (FRA:E4NA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Arovella Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Arovella Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Arovella Therapeutics (FRA:E4NA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arovella Therapeutics Ltd (FRA:E4NA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ALA:Australia

Address

62 Lygon Street, Level 3, Carlton, WA, AUS, 3053

Website

https://www.arovella.com

Arovella Therapeutics Ltd is a biotechnology company focused on developing therapies to treat human diseases. Its two focus areas are oncology and conditions that impact the central nervous system. The company's principal activity is the pharmaceutical development of its invariant Natural Killer T (iNKT) cell platform for the treatment of cancer.

Arovella Therapeutics (FRA:E4NA) Headlines

No Headlines